Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3)
Funding Opportunity PAR-17-128 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research project applications under the cooperative agreement (UG3/UH3) mechanism to address the development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 19, 2017 Category: Research Source Type: funding
Examination of Survivorship Care Planning Efficacy and Impact (R01)
Funding Opportunity PA-16-012 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for eva...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 23, 2015 Category: Research Source Type: funding
Examination of Survivorship Care Planning Efficacy and Impact (R21)
Funding Opportunity PA-16-011 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate developmental research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test m...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 23, 2015 Category: Research Source Type: funding
Examination of Survivorship Care Planning Efficacy and Impact (R21)
Funding Opportunity Number: PA-16-011 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: EducationHealthCFDA Number: 93.399Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with ...
Source: Grants.gov - October 23, 2015 Category: Research Tags: Education Health Source Type: funding
Examination of Survivorship Care Planning Efficacy and Impact (R01)
Funding Opportunity Number: PA-16-012 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: EducationHealthCFDA Number: 93.399Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with ...
Source: Grants.gov - October 23, 2015 Category: Research Tags: Education Health Source Type: funding
DoD Prostate Cancer Exceptional Responders Award
Funding Opportunity Number: W81XWH-15-PCRP-ERA Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementGrantCategory of Funding Activity: Science and Technology and other Research and DevelopmentCFDA Number: 12.420Eligible Applicants Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"Agency Name: DOD-AMRAAClosing Date: Sep 24, 2015Award Ceiling: $0Expected Number of Awards: 1Creation Date: May 20, 2015Funding Opportunity Description: The PCRP Exceptional Responder...
Source: Grants.gov - May 21, 2015 Category: Research Tags: Science and Technology and other Research and Development Source Type: funding
Limited Competition: Revisions to Add Phase 2 Clinical Trials Program to Experimental Therapeutics Clinical Trials Network (ETCTN)(UM1)
Funding Opportunity Number: RFA-CA-15-501 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: EducationHealthCFDA Number: 93.395Eligible Applicants Public and State controlled institutions of higher educationPrivate institutions of higher educationAgency Name: HHS-NIH11Closing Date: Jun 19, 2015Award Ceiling: $560,000Expected Number of Awards: 10Creation Date: Mar 23, 2015Funding Opportunity Description: The purpose of this Funding Opportunity Announcement (FOA) is to enhance the NCI-supported early development of experimen...
Source: Grants.gov - March 24, 2015 Category: Research Tags: Education Health Source Type: funding
Limited Competition: Revisions to Add Phase 2 Clinical Trials Program to Experimental Therapeutics Clinical Trials Network (ETCTN)(UM1)
Funding Opportunity RFA-CA-15-501 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to enhance the NCI-supported early development of experimental cancer therapeutics by merging the Phase 2 clinical trials program with the Experimental Therapeutics Clinical Trials Network (ETCTN, funded through RFA-CA-13-006) that is currently focused on Phase 1 clinical trials. The FOA invites revision applications from ETCTN UM1 awardees to expand the scope of activities by adding capabilities to conduct Phase 2 clinical trials. The goal is to integrate Phase 2 infrastructur...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 23, 2015 Category: Research Source Type: funding
Call for Nominations: 2015 Szent-Györgyi Prize for Progress in Cancer Research
Call for Nominations: 2015 Szent-Györgyi Prize for Progress in Cancer Research Nomination Deadline: September 30, 2014 The Szent-Györgyi Prize for Progress in Cancer Research was established to honor an outstanding researcher whose scientific achievements have expanded our understanding of cancer and cancer causation; whose vision has moved cancer research in new directions; and whose discoveries have resulted in notable advances in cancer prevention, diagnosis, or treatment. The Prize also promotes public awareness of the importance of basic cancer research and encourages the sustained investment needed ...
Source: ScanGrants feed - May 29, 2014 Category: Research Authors: National Foundation for Cancer Research Source Type: funding
Notice of Change in Expiration Date of PAR-14-116, "Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01)"
Notice NOT-CA-14-044 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 23, 2014 Category: Research Source Type: funding
Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01)
Funding Opportunity Number: PAR-14-116 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: EducationHealthCFDA Number: 93.39493.395Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a...
Source: Grants.gov - March 4, 2014 Category: Research Tags: Education Health Source Type: funding
Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01)
Funding Opportunity Number: PAR-11-150 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: EducationHealthCFDA Number: 93.39493.39593.397Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits ha...
Source: Grants.gov - February 27, 2014 Category: Research Tags: Education Health Source Type: funding
Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01)
Funding Opportunity PAR-14-116 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research project - cooperative agreement (U01) applications which are expected to enhance the value of quantitative imaging (QI) in clinical trials for prediction and/or measurement of response to cancer therapies. One avenue for this enhancement is to emphasize the development, optimization and validation of state-of-the-art QI methods and software tools for potential implementation in single site phase 1 or 2 clinical trials. The second avenue to enhance QI methods is to address the chall...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 26, 2014 Category: Research Source Type: funding
Call for Early Career Investigator and Underrepresented Minority Travel Fellowship Applications: Targeting VEGF-Mediated Tumor Angiogenesis in Cancer Therapy
June 19 - 20, 2014 The New York Academy of Sciences A decade after the first cancer drug targeting VEGF signaling in tumor blood vessel formation received approval by the US Food and Drug Administration (FDA), significant effort has been dedicated toward progressing the research, development, and clinical application of anti-angiogenic cancer therapies. Drawing on lessons learned from successes and failures, this conference will examine ways to improve cancer therapy by addressing urgent issues such as: i. inherent /acquired resistance, ii. immunomodulation, iii. enhanced invasiveness / metastasi...
Source: ScanGrants feed - January 6, 2014 Category: Research Authors: New York Academy of Sciences Source Type: funding
